Treatment
Third-generation EGFR-TKI clinical trials
We’re tracking 11 recruiting studies that include Third-generation EGFR-TKI, each written for real people, not researchers, below.
Recruiting studies
- NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT04324164Recruiting
Testing outcomes with EGFR pills for uncommon lung cancer mutations
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
Changsha, HunanAges 18 years+ - NCT05598528Recruiting
Study why some lung cancers don’t respond to EGFR pills
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
Changsha, HunanAges 18 years+ - NCT06363734RecruitingPhase 2
Targeted drug combo for EGFR-mutant lung cancer after resistance
This trial tests a combination of two targeted drugs (osimertinib and dalpiciclib) for people with advanced lung cancer whose tumors have a specific EGFR mutation and a change in the CDK4/6 pathway, and whose cancer has stopped responding to a third-generation EGFR targeted therapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06604689Recruiting
AI-guided brain radiation for EGFR-mutant lung cancer with brain mets
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07398599Recruiting
Double-dose targeted therapy plus chemo for lung cancer spread to brain lining
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
Nanchang, JiangxiAges 18–99 - NCT07548060RecruitingPhase 2
New drug combination for advanced lung cancer after prior treatments
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07751536Recruiting
Proton radiation and intrathecal chemo for lung cancer that has spread to the brain lining
This trial tests a combination of proton radiation to the brain and spine plus chemotherapy given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and has continued to grow despite taking a third-generation TKI medicine like osimertinib.
Hefei, AnhuiAges 18–75 - NCT07637448RecruitingPhase 2
EGFR-targeted therapy plus immunotherapy for advanced lung cancer
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18 years+ - NCT06829459RecruitingPhase 3
New drug combo vs chemo for resistant lung cancer
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
Beijing, Beijing MunicipalityAges 18 years+
What Third-generation EGFR-TKI is being studied for
Conditions with recruiting Third-generation EGFR-TKI studies.
Common questions
- Are there clinical trials studying Third-generation EGFR-TKI?
- Yes. Clin2 currently lists 11 recruiting studies that include Third-generation EGFR-TKI, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Third-generation EGFR-TKI trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Third-generation EGFR-TKI an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Third-generation EGFR-TKI or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.